Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).
Zazzi M, Kaiser R, Sönnerborg A, Struck D, Altmann A, Prosperi M, Rosen-Zvi M, Petroczi A, Peres Y, Schülter E, Boucher CA, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, Vandamme AM, van Laethem K, Wensing AM, Lengauer T, Incardona F. Zazzi M, et al. HIV Med. 2011 Apr;12(4):211-8. doi: 10.1111/j.1468-1293.2010.00871.x. Epub 2010 Aug 19. HIV Med. 2011. PMID: 20731728 Free article.
European guidelines on the clinical management of HIV-1 tropism testing.
Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA; European Consensus Group on clinical management of tropism testing. Vandekerckhove LP, et al. Lancet Infect Dis. 2011 May;11(5):394-407. doi: 10.1016/S1473-3099(10)70319-4. Epub 2011 Mar 21. Lancet Infect Dis. 2011. PMID: 21429803 Free article. Review.
Updated European recommendations for the clinical use of HIV drug resistance testing.
Vandamme AM, Sönnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vézinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L. Vandamme AM, et al. Antivir Ther. 2004 Dec;9(6):829-48. Antivir Ther. 2004. PMID: 15651743
Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.
Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D; Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Assoumou L, et al. AIDS. 2010 Jan 28;24(3):365-71. doi: 10.1097/QAD.0b013e32833338ba. AIDS. 2010. PMID: 19864933
Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine.
Assoumou L, Houssaïni A, Costagliola D, Flandre P; Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Assoumou L, et al. J Antimicrob Chemother. 2010 Apr;65(4):752-60. doi: 10.1093/jac/dkq034. Epub 2010 Feb 17. J Antimicrob Chemother. 2010. PMID: 20164199
Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ, Taieb A, Capoulade-Metay C, Katlama C, Villes V, Drobacheff-Thiebaud MC, Raffi F, Chêne G, Theodorou I, Leport C; ANRS C08 Aproco-Copilote Study Group. Laurichesse JJ, et al. HIV Med. 2010 Apr;11(4):239-44. doi: 10.1111/j.1468-1293.2009.00769.x. Epub 2009 Dec 28. HIV Med. 2010. PMID: 20050936 Free PMC article.
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.
Been-Tiktak AM, Boucher CA, Brun-Vezinet F, Joly V, Mulder JW, Jost J, Cooper DA, Moroni M, Gatell JM, Staszewski S, Colebunders R, Stewart GJ, Hawkins DA, Johnson MA, Parkin JM, Kennedy DH, Hoy JF, Borleffs JC. Been-Tiktak AM, et al. Int J Antimicrob Agents. 1999 Jan;11(1):13-21. doi: 10.1016/s0924-8579(98)00082-x. Int J Antimicrob Agents. 1999. PMID: 10075273 Clinical Trial.
358 results